ImmunityBio, Inc.
IBRX
Updated: 22/09/2026, 19:06:32
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
No summaries found.
- Share price
- $9.08
- Market cap
- $9.52B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Richard Gerald Adcock
- Employees
- 688
- IPO date
- 28/07/2015
- Beta
- 0.135
- Last dividend
- $0.00
- Day range
- $8.37 – $9.09
- 52-week range
- $1.95 – $12.43
- 1-day performance
- 7.48%
- 1-year performance
- 365.76%
- Current drawdown (1Y)
- -26.93%
- CIK
- 0001326110
- CUSIP
- 45256X103
- ISIN
- US45256X1037
- Created
- 07/12/2025, 04:39:06
- Last update
- 22/09/2026, 19:06:32
Track ImmunityBio, Inc. with an AI analyst
See which prediction-market events move IBRX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
Business Wire • STOCK • 01/06/2026, 15:51:00
IBRX and the BCG Shortage: Deals That Could Expand Demand
Zacks Investment Research • STOCK • 29/05/2026, 16:31:07
ImmunityBio: Anktiva Explained and What Comes Next
Zacks Investment Research • STOCK • 29/05/2026, 16:25:40
IBRX Stock Outlook After Q1 Results and a New FDA Review
Zacks Investment Research • STOCK • 29/05/2026, 16:25:33
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
GlobeNewsWire • STOCK • 26/05/2026, 18:00:00
IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman
PRNewsWire • STOCK • 26/05/2026, 06:52:00
IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX
GlobeNewsWire • STOCK • 25/05/2026, 21:22:00
IBRX DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX
Newsfile Corp • STOCK • 25/05/2026, 18:52:00
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp • STOCK • 25/05/2026, 14:00:00
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS
GlobeNewsWire • STOCK • 25/05/2026, 13:05:00
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
GlobeNewsWire • STOCK • 25/05/2026, 11:48:00
IBRX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Newsfile Corp • STOCK • 25/05/2026, 11:30:00